Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
8 participants
INTERVENTIONAL
2020-07-14
2021-09-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Convalescent Plasma for the Treatment of COVID-19
NCT04389710
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma
NCT04502472
CoVID-19 Plasma in Treatment of COVID-19 Patients
NCT04355897
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)
NCT04554992
Convalescent Plasma in the Treatment of Covid-19
NCT04730401
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Critical Patients
Convalescent Plasma
200-425mL convalescent plasma donated by patients previously positive for COVID-19
Severe Patients
Convalescent Plasma
200-425mL convalescent plasma donated by patients previously positive for COVID-19
High Risk
Convalescent Plasma
200-425mL convalescent plasma donated by patients previously positive for COVID-19
Health Care Providers
Convalescent Plasma
200-425mL convalescent plasma donated by patients previously positive for COVID-19
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Convalescent Plasma
200-425mL convalescent plasma donated by patients previously positive for COVID-19
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* COVID-19 disease falling into one of the following groups:
* Critical disease: respiratory failure requiring mechanical ventilation, pressor support, or multiple organ dysfunction/failure
* Severe disease: tachypnea \>/=30 per min, O2 sats \</=93% at rest, PaO2/FiO2 index \</=300mmHg
* High Risk: upper respiratory symptoms but no radiographic evidence of disease, immunocompromised, insulin-dependent diabetes, poorly controlled HIV disease, moderate to severe asthma history, severe COPD, morbid obesity (BMI \>/=40, age \>/=65 years
* Health Care Providers: health care providers at risk to exposure to COVID-19 infection or those with mild to non-severe disease
Exclusion Criteria
* History of anaphylatic reaction to blood product transfusion including hypersensitivity to immunoglobulin therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Northside Hospital, Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kent Holland, MD
Role: PRINCIPAL_INVESTIGATOR
Northside Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northside Hospital
Atlanta, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NSH 1281
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.